AG 67650

Drug Profile

AG 67650

Alternative Names: AG-67650

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AP Biosciences
  • Developer Allgenesis Biotherapeutics
  • Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 01 Aug 2017 Allgenesis Biotherapeutics in-licenses AG 67650 from AP Biosciences before August 2017 (Allgenesis Biotherapeutics website, August 2017)
  • 01 Aug 2017 Preclinical trials in Age-related macular degeneration in Taiwan before August 2017 (Allgenesis Biotherapeutics website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top